---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-044946"
form_type: "8-K"
ticker: null
cik: "0001744659"
company_name: "Akero Therapeutics, Inc."
filed_at: "2025-12-09T23:59:59+00:00"
generated_at: "2026-05-16T13:48:43.867198+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Akero Therapeutics acquired by Novo Nordisk at $54/share plus potential $6 CVR

## Summary
- Merger closed Dec 9, 2025; each share converted to $54 cash plus one CVR worth up to $6.
- Company common stock delisted from Nasdaq; trading suspended Dec 10, 2025.
- All prior directors and executive officers resigned; new directors appointed from Merger Sub.
- Certificate of incorporation and bylaws amended and restated post-merger.
- Company becomes wholly owned subsidiary of Novo Nordisk.

## SEC filing metadata
- accession: 0001140361-25-044946
- form_type: 8-K
- cik: 0001744659
- company_name: Akero Therapeutics, Inc.
- filed_at: 2025-12-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1744659/000114036125044946/0001140361-25-044946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1744659/000114036125044946/ef20060786_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-044946
- JSON: https://secwatch.observer/filing/0001140361-25-044946.json
- Plain text: https://secwatch.observer/filing/0001140361-25-044946.txt

## Source-grounded claims
- claim_id: 8c1b28db53ade97608444db6935fd2b925739751
  claim: Akero Therapeutics, Inc.: Certificate of incorporation was amended and restated in its entirety.
  evidence_excerpt: the Company’s certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety to be in the form of Annex II to the Merger Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1744659/000114036125044946/0001140361-25-044946-index.htm
- claim_id: dde0d610484a252ceb4e25930b4ebdff51998c6f
  claim: Akero Therapeutics, Inc.: Bylaws were amended and restated in their entirety to conform to the bylaws of Merger Sub.
  evidence_excerpt: the Company’s bylaws, as in effect immediately prior to the Effective Time, were amended and restated in their entirety to conform to the bylaws of Merger Sub
  evidence_url: https://www.sec.gov/Archives/edgar/data/1744659/000114036125044946/0001140361-25-044946-index.htm
- claim_id: 05f2ab460ba152348f62026575ab23f2f23968ae
  claim: Akero Therapeutics, Inc. underwent a change of control involving Novo Nordisk A/S for $54.00 per share in cash plus contingent value rights (closed 2025-12-09).
  evidence_excerpt: prior to the Effective Time (other than Excluded Shares and Dissenting Shares) was automatically cancelled and converted into the right to receive (i) cash in an amount equal to $54.00, without interest thereon and subject to any applicable tax withholdings (the “ Closing Consideration ”) and (ii) one contractual contingent value right (a “ CVR ”) representing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1744659/000114036125044946/0001140361-25-044946-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.